Document is current
Any future updates will be listed below
-
Authors
Weng, Yuhan https://orcid.org/0009-0005-3453-1402
Guccione, Caitlin
McDonald, Daniel
Oles, Renee
Devkota, Suzanne https://orcid.org/0000-0001-5575-9362
Kopylova, Evguenia
Sepich-Poore, Gregory D. https://orcid.org/0000-0002-3443-3715
Salido, Rodolfo A.
Din, M. Omar
Song, Se Jin https://orcid.org/0000-0003-0750-5709
Curtius, Kit
Chu, Hiutung https://orcid.org/0000-0001-7489-0446
Bartko, Andrew https://orcid.org/0000-0002-1237-2747
Hasty, Jeff
Knight, Rob https://orcid.org/0000-0002-0975-9019
- License Information
-
More Information
Article History
Received: 7 April 2025
Accepted: 6 October 2025
First Online: 20 November 2025
Competing interests
: The authors declare the following competing interests: D.M. is a consultant for BiomeSense, Inc., has equity, and receives income. E.K. is the managing director of Clarity Genomics. M.O.D. has equity in GenCirq. K.C. has research grant support from Phathom Pharmaceuticals. A.B. is a founder of Guilden Corporation and is an equity owner. R.K. is a scientific advisory board member and consultant for BiomeSense, Inc., has equity, and receives income. He is a scientific advisory board member and has equity in GenCirq. He is a consultant for DayTwo, and receives income. He has equity in and acts as a consultant for Cybele. He is a co-founder of Biota, Inc., and has equity. J.H. is a co-founder of GenCirq Inc., which focuses on cancer therapeutics. He is on the Board of Directors and has equity in GenCirq. His spouse is employed part-time for the bookkeeping and to support employees with Human Resources. The terms of these arrangements have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies. The remaining authors declare no competing interests.
